{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T15:06:27Z","timestamp":1764860787818,"version":"3.46.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>This review will attempt to summarize the most potentially impactful new data on the treatment of systemic vasculitic conditions, including ANCA-associated vasculitis (AAV), giant cell arteritis, polymyalgia rheumatica and Takayasu arteritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Rituximab, cyclophosphamide, upadacitinib, baricitinib, mepolizumab, benralizumab and tocilizumab have all had new clinical trials and observational data from real world registries showing their treatment benefit in various vasculitic conditions. The recently developed classification criteria for five different vasculitic conditions (AAV, giant cell arteritis, and Takayasu arteritis), very important for clinical trial recruitment, have serious methodological issues that continue to be present in the new criteria sets and these need to be addressed before they can be widely adopted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Important new data over the last several years for the treatment of systemic vasculitis have the potential to change how these conditions are managed. The remaining issues outlined in this review still need to be addressed to best serve vasculitis patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001129","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:00:32Z","timestamp":1760101232000},"page":"6-11","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of systemic vasculitis"],"prefix":"10.1097","volume":"38","author":[{"given":"Yusuf","family":"Yazici","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"R1-20251204","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis","volume":"81","author":"Robson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R2-20251204","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/art.41983","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis","volume":"74","author":"Suppiah","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R3-20251204","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R4-20251204","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/ard-2022-223482","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for Takayasu arteritis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R5-20251204","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1002\/art.42325","article-title":"2022 American College of Rheumatology\/EULAR classification criteria for giant cell arteritis","volume":"74","author":"Ponte","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R6-20251204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/BOR.0000000000000916","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria sets for three types of antineutrophilic cytoplasmic antibody-associated vasculitis","volume":"35","author":"Yazici","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"R7-20251204","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/art.42269","article-title":"A methodologic problem and a conceptual issue related to the new 2022 antineutrophil cytoplasmic antibody-related vasculitis criteria sets: comment on criteria sets approved by the American College of Rheumatology Board of Directors and the European Alliance of Associations for Rheumatology Executive Committee","volume":"74","author":"Yazici","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R8-20251204","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/rheumatology\/kead161","article-title":"Validation of the 2022 American College of Rheumatology\/EULAR classification criteria for Takayasu arteritis","volume":"62","author":"Tomelleri","year":"2023","journal-title":"Rheumatology"},{"key":"R9-20251204","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3899\/jrheum.2023-0338","article-title":"Disease classification criteria for diagnosis or for research? In fact, for neither","volume":"51","author":"Yazici","year":"2024","journal-title":"J Rheumatol"},{"key":"R10-20251204","first-page":"319","article-title":"Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis","volume":"0","author":"Nagle","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R11-20251204","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"R12-20251204","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.ard.2025.01.040","article-title":"Correspondence on \u2018Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis\u2019 by Nagle et al","volume":"84","author":"Yazici","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R13-20251204","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.42843","article-title":"Risk of relapse of antineutrophil cytoplasmic antibody\u2013associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids","volume":"76","author":"Junek","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R15-20251204","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/art.43146","article-title":"Long-term safety and efficacy of mepolizumab in eosinophilic granulomatosis with polyangiitis","volume":"77","author":"Wechsler","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"R16-20251204","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"R17-20251204","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"R19-20251204","doi-asserted-by":"crossref","first-page":"103338","DOI":"10.1016\/j.jaut.2024.103338","article-title":"Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors","volume":"149","author":"Sorin","year":"2024","journal-title":"J Autoimmun"},{"key":"R20-20251204","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A phase 3 trial of upadacitinib for giant-cell arteritis","volume":"392","author":"Blockmans","year":"2025","journal-title":"N Engl J Med"},{"key":"R21-20251204","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"New Engl J Med"},{"key":"R22-20251204","doi-asserted-by":"crossref","first-page":"e619","DOI":"10.1016\/S2665-9913(21)00152-1","article-title":"Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study","volume":"3","author":"Christ","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"R23-20251204","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/rheumatology\/keae378","article-title":"Magnetic resonance imaging to monitor disease activity in giant cell arteritis treated with ultra-short glucocorticoids and tocilizumab","volume":"64","author":"Christ","year":"2025","journal-title":"Rheumatology"},{"key":"R24-20251204","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/rheumatology\/kead215","article-title":"Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study","volume":"63","author":"Muratore","year":"2024","journal-title":"Rheumatology"},{"key":"R25-20251204","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1093\/rheumatology\/keae400","article-title":"Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study","volume":"64","author":"Muratore","year":"2025","journal-title":"Rheumatology"},{"key":"R26-20251204","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/S2665-9913(24)00270-4","article-title":"Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial","author":"Saraux","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"R27-20251204","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R28-20251204","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/rheumatology\/kead426","article-title":"Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study","volume":"63","author":"Assaraf","year":"2024","journal-title":"Rheumatology"},{"key":"R29-20251204","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1093\/rheumatology\/keaf240","article-title":"The 2025 British Society for Rheumatology management recommendations for ANCA-associated vasculitis","volume":"64","author":"Biddle","year":"2025","journal-title":"Rheumatology"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T15:01:19Z","timestamp":1764860479000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001129","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"type":"print","value":"1040-8711"},{"type":"electronic","value":"1531-6963"}],"subject":[],"published":{"date-parts":[[2025,10,3]]}}}